Ruth Hook (@ruth_hook_) header
Ruth Hook (@ruth_hook_) profile picture

immunology & tissue stem cell biology- currently solid tumor oncology @rockefelleruniv 🇺🇸🇮🇪🇫🇮 citizen- reading, running, climbing, folk harp etc

NYC
Joined October 2015
Photo by Ruth Hook (@ruth_hook_)Photo by Ruth Hook (@ruth_hook_)Photo by Ruth Hook (@ruth_hook_)Photo by Ruth Hook (@ruth_hook_)Photo by Ruth Hook (@ruth_hook_)Photo by Ruth Hook (@ruth_hook_)Photo by Ruth Hook (@ruth_hook_)Photo by Ruth Hook (@ruth_hook_)Photo by Ruth Hook (@ruth_hook_)
has there ever been a problem in science where the solution hasn't been "it's far more nuanced, complex, & context dependent than we thought" just once it would be nice for overwhelming complexity to suddenly simplify itself with additional understanding from a new discovery
126
55
21
1,192
228,295
one of my scientific heroes is paul frenette (circadian rhythms in hematopoietic trafficking, neural regulation of hematopoiesis) whose lab motto here in new york was "in vivo veritas"
3
12
1
280
9,910
Ruth Hook retweeted
I discussed this fairly extensively with @owl_posting on our podcast together, but I agree the "scale up existing assay" approach is quite flawed. If we examine sequencing, imagine where the field would have stalled if we just tried to scale Sanger. This would have been somewhat helpful, but ultimately not transformative. Protein engineering is very reliant on data that comes from DNA sequencing, especially in the age of barcoded DNA libraries, but this would not have been possible even with 1000x scaled up Sanger. NGS broke open an entire industry's worth of applications that Sanger simply couldn't deliver. This is why I find the fully automated labs concept quite fraught. Sure, it helps you commodify particular assays, but you just get leap-frogged whenever someone creates the next NGS. Obviously you need both, but right now we're getting 95% of one and 5% of the other, should be much closer to 50-50. And obviously listen to our interview on @corememory open.spotify.com/episode/5Nf…
Maybe controversial: the conversation about scientific bottlenecks is overfocused on automation. New measurement technologies deserve more attention. You could automate an assay that needs an entire facility – or you could REINVENT the assay so that it fits into just a few tubes.
3
11
2
108
6,414
I need all the AI people to stop saying "biology" when they mean "medicine" or "drug development"
31
74
8
754
33,739
lab mate proposed to me this morning!!! with new midiprepped lentiviral packaging plasmids ❤️
6
138
3,800
GLPs came to us through NIH grants funding basic research gaps in our understanding of insulin secretion and glucagon production in the 80s/Svetlana Mojsov and Joel Habener at Mass Gen
the primary thing ive learned over the past 3~ months of grantmaking is that the NIH is incredibly impressive. people make fun of it without thinking too much about how much of a logistical nightmare it is to distribute $50B+ per year while also giving everyone a fair shot
3
1
93
7,021
Ruth Hook retweeted
The wildest part of the Nobel drama is that the least-discussed guy left out, Zhuo-Hua Pan, has a better claim on the tech than Boyden and he’s the only one with any shot of turning opto into a real therapy….he just wasn’t at a prestigious institution statnews.com/2016/09/01/opto…
26
117
9
674
49,023
why did they feng zhang boyden
3
5
2
211
24,389
love sholto and also non-sequitur mcf-7s have rampant L1PA2 activity and a bunch of wild comutations- I threw them away with such gusto with the helas during the last LN2 clean
Retracted today from Scientific Reports after my comments. The unlikely collaboration involved authors from Ethiopia, Chile, India, China, and South Korea. Two of the figures were easily identifiable as AI slop.
1
14
1,462
It’s fun to make predictions. Here’s a new one: OpenAI has solved one of molecular biology’s classic problems: decoding the entire noncoding genome via determining the structure, function, and regulatory logic of every single ncRNA. They will announce it before the IPO.
7
3
1
177
12,892
People like Elizabeth aren’t rare; you’ve already met plenty. There’s no cautionary tale or admirable anti-hero that you don’t already know. When she comes home in several years, she will return to the things many people want — two kids, a loving partner whose flavor of crazy matches hers… some VC will write her a $50M check towards whatever she does next because it’ll be funny to say they invested in Lizzie. She’s not a victim; she’s a criminal. Most of the bad things she did, she didn’t get charged for. She’s not a role model, and turning her into a punchline gives her power. There are people who enable her — allocating the world’s limited resources and attention towards her vision. Those people should be more embarrassed than they act like they are. Ps I’ve never met @ElizabethHolmes, but Billy blocked me because I’m related to “the enemy”.
YOU CAN SEE EVERYTHING, a documentary by Nathan Fielder and Lance Oppenheim. Featuring Elizabeth Holmes. Only in theaters this October.
10
11
165
49,333
guess which number is closest to the amount of money we've spent trying to make drugs for sepsis since 1970
33%5 billion
13%10 billion
17%12.5 billion
37%15 billion
210 votes • Final results
3
1
14
2,243
I don't know why I'm so fascinated with this particular long car crash in drug development, I can't stop reading about it
1
10
640
had an entire 20m conversation with a postdoc today where he thought I was talking about HLA B27 being wildly variable and uncharacterized when I was talking about B-27 for neuronal/stem cell diffs (which is wildly variable lot to lot primarily due to the BSA), the longest august
2
1
38
3,454
❤️
Finally get to say that a drug I helped discover is in human trials. The team sprinted for 6 years on this. We went from a thought-to-be undruggable target to profound degradation very quickly, and then several more years optimizing for human dosing. That speaks to the power of DNA encoded libraries and modularity of TPD, and the hard road that is drug *development*. ir.nurixtx.com/news-releases…
19
2,594
regular reminder antigen presenting cells donate telomeres at the immunological synapse and t cells then incorporate into their genome/you can use this as an excuse to mentally checkout whenever someone brings up telomeres if you like
3
7
93
4,012
Ruth Hook retweeted
It would be great if we could monitor anything in the body continuously. The continuous glucose monitor (CGM) was a great start, but there are so many interesting molecules to human health beyond glucose, but no one has successfully made monitors that work for other things. This is largely because display-based screening techniques for binders are detached from the ground truth physiologic data that matters. It would great to have a screening method that is coupled to a readout, like a GFP or nanopore, so that readout of a designed binder produces a number that is more meaningful. In a preprint with @mu_anand and other folks at Caltech, we ask whether existing architectures around protein binders tied to a GFP reporter can serve as this screening vehicle to speed up ML-design of new monitoring proteins. We took 18 OpuBC-cpGFP biosensors that our lab previously evolved toward nicotine, SSRIs, and other neural drugs, and screened them against 63 human health-relevant compounds, creating function data for 1134 sensor-ligand pairs. 124 pairs came back at a signal level we deemed suitable to begin directed evolution campaigns, with a little over half of those having readouts at a dynamic range that could make them immediately usable in application today. In total about a third of our compounds in our limited screen found a paired sensor worth evolving on. We ultimately think that PBP-cpGFPs could be useful to increase the hit rate of initial screens of possible continuous monitors. You can read it below.
11
19
4
96
16,963
Ruth Hook retweeted
Why haven't organoids solved all of drug discovery? (5.8k words, 26 minutes) here, i try to answer a question that i imagine has been on peoples minds for awhile. first essay of a three part series over organoids, because this subject is complicated owlposting.com/p/why-havent-…
15
52
16
389
82,353
Ruth Hook retweeted
It pains me to say this but OpenEvidence AI is superior to UpToDate (and it’s free!) @openevidence
40
41
12
588
80,340
this paper came out almost five years ago and imo it should have been national news based on how many older couples are working with such a low n of embryos to begin with tl/dr: (~oversimplified, please read their work!) early aneuploidy is normal and development autocorrects
2
1
1
64
5,152
meanwhile in science
22
2,777
158
28,740
334,801